KyriacouA, KyriacouA, MakrisKC, et al.Weight gain following treatment of hyperthyroidism-A forgotten tale. Clin Obes, 2019; 9(5):e12328; doi: 10.1111/cob.12328
2.
TörringO, WattT, SjölinG, et al.Impaired quality of life after radioiodine therapy compared to antithyroid drugs or surgical treatment for Graves’ hyperthyroidism: A long-term follow-up with the thyroid-related patient-reported outcome questionnaire and 36-item short form health status survey. Thyroid, 2019; 29(3):322–331; doi: 10.1089/thy.2018.0315
3.
OkoloD, AkpanumoB, OkekeCH, et al.The influence of obesity on quality of life: A systematic review. J Adv Med Med Res, 2024; 36(11):267–279; doi: 10.9734/jammr/2024/v36i115637
4.
KyriacouA, KyriacouA, LamnisosD, et al.Weight gain after treatment of hyperthyroidism is associated with impairment of quality of life. Thyroid, 2026; 36(1):25–35; doi: 10.1177/10507256251404868
5.
LindoA, AlsenS, ForsA, et al.In the shadow of Graves’ disease: A qualitative interview study of patients’ experiences conducted at a secondary referral centre in Sweden. BMJ Open, 2025; 15(11):e098238; doi: 10.1136/bmjopen-2024-098238
6.
WattT, HegedüsL, GroenvoldM, et al.Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO. Eur J Endocrinol, 2010; 162(1):161–167; doi: 10.1530/eje-09-0521
7.
CramonPK, BjornerJB, GroenvoldM, et al.Implementation of thyroid-related patient-reported outcomes in routine clinical practice. Front Endocrinol (Lausanne), 2022; 13:1000682; doi: 10.3389/fendo.2022.1000682
8.
WiersingaWM. Quality of life in Graves’ ophthalmopathy. Best Pract Res Clin Endocrinol Metab, 2012; 26(3):359–370; doi: 10.1016/j.beem.2011.11.001
